|
|
Home  CMSC Online For MS Professionals Presentations
|
Advances in MS Therapy |
|
|
Advances in Multiple Sclerosis Therapy
A continuing medical education certified Webcast-on-Demand
Sponsored by SCEPTER™. Supported by an educational grant from Bayer HealthCare Pharmaceuticals
Release Date: August 17, 2007
Termination Date: August 17, 2008
Estimated time to complete this activity: 1 hour
(Click here to go to the CME program)
STATEMENT OF NEEDS
Multiple sclerosis (MS) presents numerous challenges to health care providers and patients, whose shared goal is to minimize functional impairment and improve quality of life. Educating physicians about treatment options by comparing the efficacy and safety of available agents will help improve clinical outcomes. Clinicians should also explore any issues that may contribute to poor adherence to therapy, including depression, other comorbidities, or problems with adverse effects. In addition to targeting the disease process, the treatment of MS involves managing symptoms such as bowel and bladder problems, cognitive and mood disorders, and motor weakness and spasticity. It is also critical for patients to have realistic expectations as to treatment outcomes. Educating health care professionals about available therapeutic options and effective strategies for managing MS symptoms, using the most current clinical data, will further clinicians' understanding of this debilitating disease and improve patient care.
CME INFORMATION
Educational Objectives - Correctly diagnose MS based on interpreting magnetic resonance imaging (MRI) findings, the current McDonald criteria, and other diagnostic criteria
- Initiate early pharmacologic intervention in symptomatic and asymptomatic patients with MS, based on clinical trial reports of efficacy, safety, and delay in disability progression
- Apply current evidence regarding MS drug treatments to select appropriate therapy to treat patients who experience a relapse, based on an understanding of their various benefits and risks
Audience
This activity is designed for neurologists and other health care professionals who treat patients with MS or suspected MS. There are no prerequisites for participation in this activity.
Accreditation Statement
SCEPTER™ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Quintiles, through its Learning and Development department, is a California Board of Registered Nursing approved Continuing Education Provider. Eligible participants will be granted 1.0 contact hours for this course.
Quintiles adheres to the standards set forth by the California Board of Registered Nursing in granting contact hours.
For International participants or for those participants in the United States who are not nurses, please contact your local licensing board to ask if they accept these contact hours.
Credit Designation Statement
SCEPTER designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This content has been reviewed for fair balance and bias by:
Stephen S. Kamin, MD
Associate Professor and Acting Chair
Department of Neurology and Neurosciences
University of Medicine and Dentistry of New Jersey (UMDNJ)
New Jersey Medical School
FACULTY - Program Chair
Fred D. Lublin, MD
Professor of Neurology
Mount Sinai School of Medicine
New York, New York - Presenting Faculty
June Halper, MSCN, ANP, FAAN
Executive Director
Multiple Sclerosis Center at Holy Name Hospital
Teaneck, New Jersey
DISCLOSURE INFORMATION
Policy on Disclosure
SCEPTER adheres to the ACCME Essential Areas and Policies, including the Standards for Commercial Support, regarding industry support of CME. Disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships, as well as the discussion of unlabeled or unapproved use of any drug, device, or procedure by the faculty, will be disclosed to learners.
Faculty Disclosure
The faculty participating in this activity have reported the following:
Fred D. Lublin, MD, serves on the speakers bureau and is a consultant for Bayer Healthcare Pharmacueticals, Pfizer Inc, Serono, and Teva Pharmaceuticals. He is a consultant for Biogen Idec, Daiichi Sankyo, Eisai Inc., Genentech, MediciNova Inc., and Novartis. He has also received grant support from Acorda, Biogen Idec, and Teva Pharmaceuticals. Fred D. Lublin, MD, reports that his presentation will not include discussion of any investigational or unlabled use of a product.
June Halper, MSCN, ANP, FAAN, is a consultant for Bayer Healthcare Pharmacueticals. She has received honoraria from and serves on the speakers bureau for Teva Neuroscience. She also reports that her presentation will not include discussion of any investigational or unlabled use of a product.
CME Content Reviewer Declaration
Stephen S. Kamin, MD, has no significant financial relationships to disclose.
Educational Partner Disclosure
The internal staff of Quintiles Medical Education reports no conflict or financial interest with any manufacturers of products or providers of services.
This activity does not contain information on commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.
Disclaimer
The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor, the educational partner, or the supporter. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.
Click here to go to the CME program
|
|
